Zealand Pharma A/S (VIE:ZEAL)
Austria · Delayed Price · Currency is EUR | Market Cap | 2.82B -49.2% |
| Revenue (ttm) | 1.23B +14,598.9% |
| Net Income | 864.30M |
| EPS | 12.08 |
| Shares Out | n/a |
| PE Ratio | 3.26 |
| Forward PE | 16.41 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 17 |
| Open | 39.23 |
| Previous Close | 39.99 |
| Day's Range | 39.17 - 40.15 |
| 52-Week Range | 34.46 - 40.82 |
| Beta | n/a |
| RSI | 70.86 |
| Earnings Date | May 7, 2026 |
About Zealand Pharma
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglu... [Read more]
News
Zealand Pharma A/S at Barclays Global Healthcare Conference Transcript
Zealand Pharma A/S at Barclays Global Healthcare Conference Transcript
Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly
Roche and Zealand Pharma's obesity drug petrelintide showed up to 11% weight loss in a Phase 2 trial with strong safety results. ... Full story available on Benzinga.com
Zealand Pharma slump wipes billions off its value after obesity drug data disappoints
Shares in Zealand Pharma tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity drug petrelintide fe...
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Zealand Pharma to accelerate drug development for obesity, metabolic disease
Danish biotech Zealand Pharma said on Thursday it will accelerate development and expand its research as it seeks to differentiate its experimental obesity drug candidates in an increasingly competiti...
Zealand Pharma scraps obesity drug candidate, citing crowded market, Bloomberg News reports
Zealand Pharma is halting development of a potential next-generation obesity drug after concluding the market has become too crowded for it to stand out, Bloomberg News reported on Thursday, citing an...
Zealand Pharma may sell future obesity drug direct to patients, amid market shifts
Zealand Pharma is considering a direct-to-patient sales model for its experimental weight-loss drug alongside traditional insurer channels, its CEO told Reuters in an interview on Monday, citing shift...
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Zealand Pharma Obesity Therapy Shows Positive Trial Results
Zealand Pharma said its obesity treatment dapiglutide showed positive topline results in its latest trial, demonstrating its further potential for weight loss and to treat obesity-related comorbiditie...
European stocks recover after Trump delays EU tariffs in hopes of deal
European shares kicked off the week on a positive note on Monday, recouping the previous session's losses, as markets heaved a sigh of relief after U.S. President Donald Trump delayed his threat to im...
Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit
Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives a...
Zealand Pharma begins mid-stage trial for obesity drug candidate in people with type 2 diabetes
Danish biotechnology company Zealand Pharma said on Thursday it had enrolled the first patient in a mid-stage trial with its weight-loss drug candidate petrelintide in people with overweight or obesit...
Zealand Pharma Goes on Hiring Spree as It Gears Up for Obesity Tie-Up With Roche
The Danish biotech's recruitment drive began last summer when data from an early-stage trial of the drug—petrelintide—showed its potential.
Zealand Pharma's new drug petrelintide will help people lose weight: CEO
Zealand Pharma CEO Adam Steensberg discusses the company's new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate. Shares of Zealand Pharma jumped as...
Roche to develop, commercialize obesity drug with Zealand Pharma
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wedn...
Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight and obesity
Basel, 12 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma (Nasdaq Copenhagen: ZEAL) (CVR...
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
Press Release – No. 3 / 2025 Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results Copenhagen, Denmark, February 13, 2025 – Zealand Pharma A/S (...
Zealand Pharma CEO says Novo's CagriSema data supports monotherapy approach to cagrilintide
The CEO of Danish drugmaker Zealand Pharma said on Friday that data posted by Novo Nordisk's late-stage study of its next-generation obesity drug CagriSema supported Zealand's own monotherapy approach...
US FDA declines to approve Zealand Pharma's bowel disease drug
The U.S. Food and Drug Administration declined to approve Zealand Pharma's bowel disease drug, the company said on Thursday.
Zealand Pharma starts Phase 2b trial for obesity drug candidate petrelintide
Danish biotechnology company Zealand Pharma said on Tuesday it had enrolled the first patient in its so-called Phase 2b ZUPREME-1 trial with its obesity treatment candidate petrelintide.
Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4
Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1, 2024 – Zealand Pharma A/...